vs
简柏特（EGP）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是简柏特的1.1倍（$207.3M vs $190.3M），简柏特净利率更高（49.7% vs -62.0%，领先111.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.1%），简柏特自由现金流更多（$126.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.4%）
简柏特是全球领先的信息技术服务、咨询及外包服务商，总部位于美国纽约，注册地为百慕大，最初创立于印度古尔冈。目前公司全球员工超12.5万名，服务覆盖30余个国家，于纽交所上市，2023年营收达44.8亿美元。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EGP vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$190.3M
营收增速更快
RARE
高出16.8%
9.1%
净利率更高
EGP
高出111.8%
-62.0%
自由现金流更多
EGP
多$227.5M
$-100.8M
两年增速更快
RARE
近两年复合增速
9.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $190.3M | $207.3M |
| 净利润 | $94.6M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 49.7% | -62.0% |
| 营收同比 | 9.1% | 25.9% |
| 净利润同比 | 59.2% | 3.5% |
| 每股收益（稀释后） | $1.77 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGPRARE
| Q1 26 | $190.3M | — | ||
| Q4 25 | $187.5M | $207.3M | ||
| Q3 25 | $182.1M | $159.9M | ||
| Q2 25 | $177.3M | $166.5M | ||
| Q1 25 | $174.4M | $139.3M | ||
| Q4 24 | $164.0M | $164.6M | ||
| Q3 24 | $162.9M | $139.5M | ||
| Q2 24 | $159.1M | $147.0M |
净利润EGPRARE
| Q1 26 | $94.6M | — | ||
| Q4 25 | $67.8M | $-128.6M | ||
| Q3 25 | $67.0M | $-180.4M | ||
| Q2 25 | $63.3M | $-115.0M | ||
| Q1 25 | $59.4M | $-151.1M | ||
| Q4 24 | $58.7M | $-133.2M | ||
| Q3 24 | $55.2M | $-133.5M | ||
| Q2 24 | $55.3M | $-131.6M |
营业利润率EGPRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% |
净利率EGPRARE
| Q1 26 | 49.7% | — | ||
| Q4 25 | 36.1% | -62.0% | ||
| Q3 25 | 36.8% | -112.8% | ||
| Q2 25 | 35.7% | -69.0% | ||
| Q1 25 | 34.1% | -108.5% | ||
| Q4 24 | 35.8% | -80.9% | ||
| Q3 24 | 33.9% | -95.7% | ||
| Q2 24 | 34.8% | -89.5% |
每股收益（稀释后）EGPRARE
| Q1 26 | $1.77 | — | ||
| Q4 25 | $1.27 | $-1.28 | ||
| Q3 25 | $1.26 | $-1.81 | ||
| Q2 25 | $1.20 | $-1.17 | ||
| Q1 25 | $1.14 | $-1.57 | ||
| Q4 24 | $1.17 | $-1.34 | ||
| Q3 24 | $1.13 | $-1.40 | ||
| Q2 24 | $1.14 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.4M | $421.0M |
| 总债务越低越好 | $1.6B | — |
| 股东权益账面价值 | $3.6B | $-80.0M |
| 总资产 | $5.5B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资EGPRARE
| Q1 26 | $31.4M | — | ||
| Q4 25 | $1.0M | $421.0M | ||
| Q3 25 | $3.0M | $202.5M | ||
| Q2 25 | $32.9M | $176.3M | ||
| Q1 25 | $20.5M | $127.1M | ||
| Q4 24 | $17.5M | $174.0M | ||
| Q3 24 | $17.0M | $150.6M | ||
| Q2 24 | $39.4M | $480.7M |
总债务EGPRARE
| Q1 26 | $1.6B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — |
股东权益EGPRARE
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $-80.0M | ||
| Q3 25 | $3.5B | $9.2M | ||
| Q2 25 | $3.4B | $151.3M | ||
| Q1 25 | $3.3B | $144.2M | ||
| Q4 24 | $3.3B | $255.0M | ||
| Q3 24 | $2.8B | $346.8M | ||
| Q2 24 | $2.8B | $432.4M |
总资产EGPRARE
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.4B | $1.5B | ||
| Q3 25 | $5.4B | $1.2B | ||
| Q2 25 | $5.2B | $1.3B | ||
| Q1 25 | $5.1B | $1.3B | ||
| Q4 24 | $5.1B | $1.5B | ||
| Q3 24 | $4.8B | $1.5B | ||
| Q2 24 | $4.7B | $1.6B |
负债/权益比EGPRARE
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.60× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $126.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 66.6% | -48.6% |
| 资本支出强度资本支出/营收 | 8.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.50× | — |
| 过去12个月自由现金流最近4个季度 | $771.1M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流EGPRARE
| Q1 26 | $142.3M | — | ||
| Q4 25 | $480.7M | $-99.8M | ||
| Q3 25 | $138.9M | $-91.4M | ||
| Q2 25 | $143.4M | $-108.3M | ||
| Q1 25 | $133.7M | $-166.5M | ||
| Q4 24 | $416.6M | $-79.3M | ||
| Q3 24 | $122.9M | $-67.0M | ||
| Q2 24 | $122.9M | $-77.0M |
自由现金流EGPRARE
| Q1 26 | $126.7M | — | ||
| Q4 25 | $404.9M | $-100.8M | ||
| Q3 25 | $120.3M | $-92.7M | ||
| Q2 25 | $119.2M | $-110.7M | ||
| Q1 25 | $113.9M | $-167.8M | ||
| Q4 24 | $357.3M | $-79.5M | ||
| Q3 24 | $108.5M | $-68.6M | ||
| Q2 24 | $102.8M | $-79.0M |
自由现金流率EGPRARE
| Q1 26 | 66.6% | — | ||
| Q4 25 | 216.0% | -48.6% | ||
| Q3 25 | 66.0% | -58.0% | ||
| Q2 25 | 67.2% | -66.5% | ||
| Q1 25 | 65.3% | -120.5% | ||
| Q4 24 | 217.8% | -48.3% | ||
| Q3 24 | 66.6% | -49.2% | ||
| Q2 24 | 64.6% | -53.7% |
资本支出强度EGPRARE
| Q1 26 | 8.2% | — | ||
| Q4 25 | 40.5% | 0.5% | ||
| Q3 25 | 10.2% | 0.8% | ||
| Q2 25 | 13.7% | 1.5% | ||
| Q1 25 | 11.3% | 1.0% | ||
| Q4 24 | 36.1% | 0.1% | ||
| Q3 24 | 8.9% | 1.2% | ||
| Q2 24 | 12.6% | 1.4% |
现金转化率EGPRARE
| Q1 26 | 1.50× | — | ||
| Q4 25 | 7.10× | — | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 2.26× | — | ||
| Q1 25 | 2.25× | — | ||
| Q4 24 | 7.10× | — | ||
| Q3 24 | 2.23× | — | ||
| Q2 24 | 2.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EGP
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
